Foghorn Therapeutics annual return on equity
2020
2021
2022
Foghorn Therapeutics Return on Equity (ROE) Growth & History (FHTX)
Foghorn Therapeutics's return on equity was −224.54% for fiscal 2022.
View full Foghorn Therapeutics company overviewFoghorn Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-12-31 | −224.54% | −141.17 pp |
| 2021 | 2021-12-31 | −83.37% | +153.17 pp |
| 2020 | 2020-12-31 | −236.54% | — |
Foghorn Therapeutics quarterly return on equity
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2022 | 2022-12-31 | −236.43% | −203.66 pp |
| Q3 2022 | 2022-09-30 | −71.63% | −43.46 pp |
| Q2 2022 | 2022-06-30 | −45.51% | −25.36 pp |
| Q1 2022 | 2022-03-31 | −31.80% | −14.86 pp |
| Q4 2021 | 2021-12-31 | −32.77% | +289.96 pp |
| Q3 2021 | 2021-09-30 | −28.17% | — |
| Q2 2021 | 2021-06-30 | −20.15% | — |
| Q1 2021 | 2021-03-31 | −16.94% | — |
| Q4 2020 | 2020-12-31 | −322.73% | — |
Foghorn Therapeutics return on equity trends
Between the periods ended 2020-12-31 and 2022-12-31, Foghorn Therapeutics's return on equity increased from −236.54% to −224.54%, a change of +12.01 percentage points. The latest reported quarter, Q4 2022, shows −236.43%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Foghorn Therapeutics source filings ↗